Lifesci Capital Has Bullish Estimate for AKRO Q3 Earnings

Key Points

• Lifesci Capital analysts have raised earnings estimates for Akero Therapeutics, projecting a Q3 2025 earnings per share (EPS) of ($0.90), an improvement from the previous estimate of ($0.95).
• Several analysts have maintained a "buy" rating on Akero Therapeutics, with an average price target of $81.57, reflecting strong market confidence in the company's prospects.
• Insider transactions revealed significant share sales, with executives selling a total of 197,906 shares recently, indicating potential caution from insiders regarding stock performance.

Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) - Investment analysts at Lifesci Capital increased their Q3 2025 earnings estimates for shares of Akero Therapeutics in a research note issued to investors on Monday, August 11th. Lifesci Capital analyst R. Katkhuda now anticipates that the company will post earnings per share of ($0.90) for the quarter, up from their previous forecast of ($0.95). The consensus estimate for Akero Therapeutics' current full-year earnings is ($3.99) per share. Lifesci Capital also issued estimates for Akero Therapeutics' Q4 2025 earnings at ($0.93) EPS and FY2025 earnings at ($3.59) EPS.

AKRO has been the subject of several other reports. TD Cowen started coverage on shares of Akero Therapeutics in a report on Monday, August 4th. They issued a "buy" rating and a $76.00 price objective for the company. Cowen started coverage on shares of Akero Therapeutics in a report on Monday, August 4th. They issued a "buy" rating for the company. Wall Street Zen raised shares of Akero Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday. Citigroup cut their price objective on shares of Akero Therapeutics from $80.00 to $78.00 and set a "buy" rating for the company in a report on Tuesday, May 13th. Finally, Bank of America raised their price objective on shares of Akero Therapeutics from $63.00 to $64.00 and gave the stock a "buy" rating in a report on Tuesday, May 27th. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $81.57.

Akero Therapeutics Stock Performance

Shares of AKRO stock traded down $0.71 during trading hours on Wednesday, hitting $49.38. 2,185,733 shares of the company were exchanged, compared to its average volume of 1,042,788. The firm has a fifty day simple moving average of $51.95 and a 200 day simple moving average of $47.27. The company has a current ratio of 12.66, a quick ratio of 16.80 and a debt-to-equity ratio of 0.02. Akero Therapeutics has a 52-week low of $21.34 and a 52-week high of $58.40. The stock has a market capitalization of $3.95 billion, a price-to-earnings ratio of -24.69 and a beta of -0.28.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last issued its quarterly earnings results on Friday, August 8th. The company reported ($0.86) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.97) by $0.11. During the same quarter in the previous year, the business posted ($0.81) EPS.

Insider Activity

In other Akero Therapeutics news, COO Jonathan Young sold 12,500 shares of the firm's stock in a transaction on Tuesday, August 12th. The shares were sold at an average price of $47.79, for a total value of $597,375.00. Following the completion of the transaction, the chief operating officer directly owned 197,484 shares of the company's stock, valued at $9,437,760.36. This trade represents a 5.95% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Timothy Rolph sold 25,000 shares of the firm's stock in a transaction on Friday, June 6th. The shares were sold at an average price of $55.04, for a total transaction of $1,376,000.00. Following the completion of the transaction, the insider directly owned 169,721 shares of the company's stock, valued at approximately $9,341,443.84. The trade was a 12.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 230,406 shares of company stock valued at $12,013,920 in the last quarter. 7.07% of the stock is currently owned by company insiders.

Institutional Trading of Akero Therapeutics

A number of hedge funds have recently made changes to their positions in AKRO. Holocene Advisors LP bought a new position in Akero Therapeutics during the second quarter valued at approximately $57,396,000. Bank of America Corp DE lifted its stake in Akero Therapeutics by 406.7% in the second quarter. Bank of America Corp DE now owns 1,320,461 shares of the company's stock worth $70,460,000 after purchasing an additional 1,059,860 shares during the last quarter. RTW Investments LP lifted its stake in Akero Therapeutics by 15.9% in the fourth quarter. RTW Investments LP now owns 6,859,823 shares of the company's stock worth $190,840,000 after purchasing an additional 940,388 shares during the last quarter. Deep Track Capital LP lifted its stake in Akero Therapeutics by 116.0% in the fourth quarter. Deep Track Capital LP now owns 1,490,000 shares of the company's stock worth $41,452,000 after purchasing an additional 800,216 shares during the last quarter. Finally, Bellevue Group AG lifted its stake in Akero Therapeutics by 58.7% in the second quarter. Bellevue Group AG now owns 1,985,272 shares of the company's stock worth $105,934,000 after purchasing an additional 734,606 shares during the last quarter.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.